ERBB2 and breast carcinoma: The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors into routine clinical practice has changed the paradigm of management of oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.